HealthQuill US
Vanda Pharmaceuticals Inc’s gastroparesis drug to treat a serious stomach condition was rejected by the Food and Drug Administration (FDA), which asked for additional studies, according to a company statement.
Drugs Health Pharma

FDA faces Vanda’s ire as it rejects firm’s gastroparesis drug application

Vanda Pharmaceuticals Inc’s gastroparesis drug to treat a serious stomach condition was rejected by the Food and Drug Administration (FDA), which asked for.

Read More
The US Food and Drug Administration approved AstraZeneca Plc’s Fasenra for treatment in adult patients with a rare inflammation of blood vessels.
Drugs Health Pharma

AstraZeneca’s rare disease drug Fasenra gets US regulator’s nod

The US Food and Drug Administration approved AstraZeneca Plc’s Fasenra for treatment in adult patients with a rare inflammation of blood vessels.

Read More
A global goal to reduce methane emissions “ seems as distant as a desert oasis” now, as about two-thirds of it comes from human activities such as fossil fuels, agriculture and landfills, researchers find.
Climate Health Pharma

Global goal to cut methane emissions as distant as a ‘desert oasis’

A global goal to reduce methane emissions “ seems as distant as a desert oasis” now, as about two-thirds of it comes from.

Read More
The World Health Organization expects the first delivery of mpox vaccines, made by Bavarian Nordic and donated by the European Union, today in Congo — the outbreak's epicentre.
Drugs Health Pharma

First batch of Bavarian Nordic’s mpox vaccines in Congo by Sept. 5 

The World Health Organization expects the first delivery of mpox vaccines, made by Bavarian Nordic and donated by the European Union, today in.

Read More
Abbott Laboratories has initiated a clinical trial to evaluate the use of the company's deep brain stimulation system to manage treatment-resistant depression, a form of major depressive disorder.
Drugs Health Pharma

Abbott starts trial on deep brain stimulation for depressive disorder

Abbott Laboratories has initiated a clinical trial to evaluate the use of the company's deep brain stimulation system to manage treatment-resistant depression, a.

Read More
Eli Lilly will license manufacturing know-how of its rheumatoid arthritis baricitinib drug, branded as Olumiant, to Egypt’s EVA Pharma to expand its access to 49 nations in Africa.
Drugs Health Pharma

Eli Lilly to license rheumatoid drug-making technology to Egypt’s EVA

Eli Lilly will license manufacturing know-how of its rheumatoid arthritis baricitinib drug, branded as Olumiant, to Egypt’s EVA Pharma to expand its access to.

Read More
Emergent BioSolutions Inc., got the US drug regulator’s approval to expand its smallpox vaccine use to treat mpox, according to a company statement.
Drugs Health Pharma

Emergent gets US drug regulator’s nod to use its smallpox vaccine for mpox

Emergent BioSolutions Inc., got the US drug regulator’s approval to expand its smallpox vaccine use to treat mpox, according to a company statement.

Read More
McKesson Corporation, the ninth-largest company by revenue in the US, will acquire Community Oncology Revitalization Enterprise Ventures, for $2.4 billion in cash to expand its oncology portfolio.
Drugs Health Pharma

McKesson Corp., to acquire Core Ventures for $2.4 billion in cash

McKesson Corporation, the ninth-largest company by revenue in the US, will acquire Community Oncology Revitalization Enterprise Ventures, for $2.4 billion in cash to expand its.

Read More
Insulet Corporation, a tubeless insulin pump maker, got clearance from the US Food and Drug Administration to add diabetes type 2 adult patients 18 years or older, to the treatment regime.
Drugs Health Pharma

Regulator okays Insulet’s insulin pump in US to treat type 2 diabetes

Insulet Corporation, a tubeless insulin pump maker, got clearance from the US Food and Drug Administration to add diabetes type 2 adult patients.

Read More
Switzerland’s Basilea Pharmaceutica Ltd. will receive $1.25 million from its partner Pfizer Inc. after the latter exceeded the sales target for a licensed anti-fungal drug in the Asia-Pacific region and China.
Drugs Medical Pharma

Basilea Pharmaceutica to get $1.25m license fee from Pfizer

Switzerland’s Basilea Pharmaceutica Ltd. will receive $1.25 million from its partner Pfizer Inc. after the latter exceeded the sales target for a licensed.

Read More